We can’t show the full text here under this license. Use the link below to read it at the source.
The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP ‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP ‐1 receptor agonists
Tirzepatide briefly slows stomach emptying like long-acting GLP-1 receptor drugs
AI simplified
Abstract
Tirzepatide delayed (GE) in participants with type 2 diabetes after multiple doses.
- In diet-induced obese mice, tirzepatide delayed GE similarly to semaglutide, but this effect disappeared after 2 weeks.
- GIP analogue alone did not influence GE or enhance GLP-1's impact on GE.
- In healthy participants, the GE delay from a single dose of tirzepatide or dulaglutide lessened after multiple doses.
- Participants with type 2 diabetes experienced a persistent GE delay with an escalation schedule of tirzepatide.
AI simplified
Key numbers
50%
Decrease in Acetaminophen Concentration
Observed in healthy participants at tirzepatide doses ≥4.5 mg.
86
Participants in Study
Composed of 33 healthy participants and 53 with T2DM.